MX2022004186A - Composiciones y métodos in vitro para potenciar la activación de células dendríticas y células t, y para inducir una respuesta inmune th-1. - Google Patents
Composiciones y métodos in vitro para potenciar la activación de células dendríticas y células t, y para inducir una respuesta inmune th-1.Info
- Publication number
- MX2022004186A MX2022004186A MX2022004186A MX2022004186A MX2022004186A MX 2022004186 A MX2022004186 A MX 2022004186A MX 2022004186 A MX2022004186 A MX 2022004186A MX 2022004186 A MX2022004186 A MX 2022004186A MX 2022004186 A MX2022004186 A MX 2022004186A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- dendritic cells
- compositions
- activation
- vitro
- Prior art date
Links
- 210000004443 dendritic cell Anatomy 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 5
- 238000000338 in vitro Methods 0.000 title abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000029662 T-helper 1 type immune response Effects 0.000 title abstract 2
- 230000004913 activation Effects 0.000 title abstract 2
- 230000002708 enhancing effect Effects 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000035800 maturation Effects 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 230000006044 T cell activation Effects 0.000 abstract 1
- 230000004041 dendritic cell maturation Effects 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
- C12N2501/052—Lipopolysaccharides [LPS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
- C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2313—Interleukin-13 (IL-13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
- C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente descripción proporciona composiciones y métodos in vitro o ex-vivo para obtener una respuesta inmunitaria Th1 específica de antígeno potenciada. Las composiciones pueden comprender células dendríticas potenciadas por activación o células T producidas in vitro. Los métodos comprenden poner en contacto células dendríticas inmaduras con un agente de maduración que comprende un agente de maduración de células dendríticas, interferón ? y un lípido activador de la inflamación que puede producir células dendríticas hiperactivadas. El método puede comprender además poner en contacto las células dendríticas en maduración con un antígeno predeterminado durante la maduración. También se proporciona un método in vitro o ex-vivo en donde las células dendríticas hiperactivas pueden usarse para inducir la activación de células T vírgenes, en donde las células T activadas pueden formularse para su administración a un individuo que necesite dicho tratamiento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962912005P | 2019-10-07 | 2019-10-07 | |
PCT/US2020/054621 WO2021071977A1 (en) | 2019-10-07 | 2020-10-07 | In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022004186A true MX2022004186A (es) | 2022-07-19 |
Family
ID=75437644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022004186A MX2022004186A (es) | 2019-10-07 | 2020-10-07 | Composiciones y métodos in vitro para potenciar la activación de células dendríticas y células t, y para inducir una respuesta inmune th-1. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20240122975A1 (es) |
EP (1) | EP4041298A1 (es) |
JP (1) | JP2022552200A (es) |
KR (1) | KR20220098351A (es) |
CN (1) | CN115461073A (es) |
AU (1) | AU2020363707A1 (es) |
BR (1) | BR112022006743A2 (es) |
CA (1) | CA3157004A1 (es) |
IL (1) | IL292009A (es) |
MX (1) | MX2022004186A (es) |
WO (1) | WO2021071977A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023503427A (ja) * | 2019-11-18 | 2023-01-30 | ザ・チルドレンズ・メデイカル・センター・コーポレーシヨン | 超活性樹状細胞は養子細胞移植に基づく持続性抗腫瘍免疫を可能にする |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016206965B2 (en) * | 2015-01-12 | 2021-03-04 | Children's Medical Center Corporation | Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists |
PL3350318T3 (pl) * | 2015-09-15 | 2022-08-16 | Northwest Biotherapeutics, Inc. | Sposoby związane z kompozycjami aktywowanych komórek dendrytycznych dla osobników z zaawansowanymi nowotworami |
-
2020
- 2020-10-07 EP EP20875158.6A patent/EP4041298A1/en active Pending
- 2020-10-07 CA CA3157004A patent/CA3157004A1/en active Pending
- 2020-10-07 JP JP2022520980A patent/JP2022552200A/ja active Pending
- 2020-10-07 AU AU2020363707A patent/AU2020363707A1/en active Pending
- 2020-10-07 US US17/766,904 patent/US20240122975A1/en active Pending
- 2020-10-07 MX MX2022004186A patent/MX2022004186A/es unknown
- 2020-10-07 CN CN202080084824.5A patent/CN115461073A/zh active Pending
- 2020-10-07 IL IL292009A patent/IL292009A/en unknown
- 2020-10-07 KR KR1020227014944A patent/KR20220098351A/ko unknown
- 2020-10-07 BR BR112022006743A patent/BR112022006743A2/pt unknown
- 2020-10-07 WO PCT/US2020/054621 patent/WO2021071977A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP4041298A1 (en) | 2022-08-17 |
KR20220098351A (ko) | 2022-07-12 |
CA3157004A1 (en) | 2021-04-15 |
WO2021071977A1 (en) | 2021-04-15 |
AU2020363707A1 (en) | 2022-04-28 |
IL292009A (en) | 2022-06-01 |
BR112022006743A2 (pt) | 2022-08-30 |
JP2022552200A (ja) | 2022-12-15 |
AU2020363707A8 (en) | 2022-05-05 |
CN115461073A (zh) | 2022-12-09 |
US20240122975A1 (en) | 2024-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rutella et al. | Granulocyte colony‐stimulating factor promotes the generation of regulatory DC through induction of IL‐10 and IFN‐α | |
Liu et al. | MSCs inhibit bone marrow-derived DC maturation and function through the release of TSG-6 | |
Tang et al. | Pro-inflammatory activated Kupffer cells by lipids induce hepatic NKT cells deficiency through activation-induced cell death | |
Wijaya et al. | HBV vaccination and HBV infection induces HBV-specific natural killer cell memory | |
AR107278A1 (es) | Procedimientos de producción de linfocitos t y linfocitos t producidos por ellos | |
Matheu et al. | Generation of bone marrow derived murine dendritic cells for use in 2-photon imaging | |
Ten Brinke et al. | Monophosphoryl lipid A plus IFNγ maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T cells with high cytolytic potential | |
Van den Bergh et al. | Monocyte-derived dendritic cells with silenced PD-1 ligands and transpresenting interleukin-15 stimulate strong tumor-reactive T-cell expansion | |
SCHwINGSHACkL et al. | Distribution and maturation of skin dendritic cell subsets in two forms of cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome | |
DK1604016T3 (da) | In vitro-fremgangsmåde til differentiering af monocytiske dendritiske precursorceller i umodne dendritiske celler | |
PH12020551151A1 (en) | Method of producing natural killer cells and composition for treating cancer | |
Itoh et al. | Streptococcal preparation OK432 promotes functional maturation of human monocyte-derived dendritic cells | |
Dobrovolskienė et al. | Tumor lysate-loaded Bacterial Ghosts as a tool for optimized production of therapeutic dendritic cell-based cancer vaccines | |
Nava et al. | An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastoma | |
Raber et al. | T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapy | |
Raïch-Regué et al. | Differential effects of monophosphoryl lipid A and cytokine cocktail as maturation stimuli of immunogenic and tolerogenic dendritic cells for immunotherapy | |
Gustafsson et al. | Tumour‐loaded α‐type 1‐polarized dendritic cells from patients with chronic lymphocytic leukaemia produce a superior NK‐, NKT‐and CD8+ T cell‐attracting chemokine profile | |
Torres-Aguilar et al. | Tolerogenic dendritic cells inhibit antiphospholipid syndrome derived effector/memory CD4+ T cell response to β2GPI | |
Karlsen et al. | Bromelain treatment leads to maturation of monocyte‐derived dendritic cells but cannot replace PGE2 in a cocktail of IL‐1β, IL‐6, TNF‐α and PGE2 | |
Wu et al. | Comparative study of dendritic cells matured by using IL‑1β, IL‑6, TNF‑α and prostaglandins E2 for different time span | |
MX2022004186A (es) | Composiciones y métodos in vitro para potenciar la activación de células dendríticas y células t, y para inducir una respuesta inmune th-1. | |
Lee IV et al. | Inhibition of CD4+ CD25+ regulatory T cell function and conversion into Th1-like effectors by a Toll-like receptor-activated dendritic cell vaccine | |
Shimabukuro-Vornhagen et al. | The ratio between dendritic cells and T cells determines whether prostaglandin E2 has a stimulatory or inhibitory effect | |
RU2012148391A (ru) | СПОСОБЫ ИДЕНТИФИКАЦИИ, ВЫДЕЛЕНИЯ, ИСТОЩЕНИЯ И ОБОГАЩЕНИЯ ПОПУЛЯЦИЙ Tr1 КЛЕТОК, ПОПУЛЯЦИИ Tr1 КЛЕТОК, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СПОСОБ МОНИТОРИНГА ЭФФЕКТА ТЕРАПИИ | |
Hernandez et al. | Inhibition of NF-κB during human dendritic cell differentiation generates anergy and regulatory T-cell activity for one but not two human leukocyte antigen DR mismatches |